Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

• Published in: Molecules (Basel, Switzerland) Vol. 28; no. 3; p. 1205
• Main Authors: Sun, Lu-Ning, Zhao, Yang, Qian, Zhou-Yi, Chen, Xiang-Long, Ma, Hong, Guo, Yu-Jiao, Shen, Hao, Wang, Yong-Qing
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.01.2023; MDPI
• Subjects: Accuracy; Acetonitrile; Acetonitriles; Blood plasma; Bruton’s tyrosine kinase inhibitor; Chromatography, High Pressure Liquid - methods; Chromatography, Liquid - methods; Drug interactions; human plasma; Humans; Inhibitor drugs; LC-MS/MS; Liquid chromatography; Lymphoma; Mass spectrometry; Methods; Physiological aspects; Plasma; Protein Kinase Inhibitors - pharmacology; Proteins; Reproducibility of Results; Retention; Tandem Mass Spectrometry - methods; Targeted cancer therapy; China; United States > US; LC-MS/MS; Bruton’s tyrosine kinase inhibitor; human plasma

Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib, zanubrutinib, ibrutinib, and its active meta...